Alnylam Pharmaceuticals Net Loss Widens In Q2

Alnylam Pharmaceuticals Inc. (ALNY) Thursday reported a net loss for the second quarter that widened from the prior year. The quarterly loss was $277.40 million or $2.29 per share, wider than $189.56 million or $1.61 per share a year ago.

On an adjusted basis, loss was $245.83 million or $2.03 per share. Wall Street analysts estimated a loss of $1.63 per share.

Revenue for the quarter gained 1.9 percent to $224.82 million from $220.55 million a year ago.

Further, the company updated that it expects to report positive results from the Apollo-B Phase 3 study of patrisiran in ATTR Amyloidosis patients with cardiomyopathy in next three weeks. The company will present the results from the Phase 2 study of cemdisiran in patients with IgAN at the 18th European Meeting on Complement in Human Disease on August 26-29, 2022 in Bern, Switzerland.

In Mid and late 2022, the pharma company will launch vutrisiran in the EU, assuming favourable adoption of the CHMP opinion.

Further, the company noted that Vir Biotechnology plans to report additional results from its Phase 2 study of ALN-HBV02 in combination with VIR-3434 in patients with chronic HBV infection in the second half of 2022.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. plans to start using American-made processors from the new advanced chip factory in Phoenix, Arizona operated by chip giant Taiwan Semiconductor Manufacturing Co., according to its Chief Executive Officer Tim Cook. At an event in the factory in Arizona, which was attended by U.S. President Joe Biden, it was also announced that TSMC will invest $40 billion in the new factory. Lidl US has recalled its 8.4 oz Favorina branded Advent Calendar, i.e., Premium Chocolate with a Creamy Filling, citing potential Salmonella contamination, the U.S. Food and Drug Administration said. The products were available for sale at Lidl stores between October 12, 2022 and December 5, 2022. They will have a BEST IF USED BY year of 2023, and barcode number of 4056489516965. Vaccine partners Pfizer Inc. and BioNTech SE are seeking emergency use authorization or EUA from the U.S. Food and Drug Administration to offer their bivalent COVID-19 vaccine to children 6 months through 4 years of age. If authorized, the vaccine would be part of a primary series for children in this age group.
Follow RTT